If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. Parkinsonism: AUSTEDO XR and AUSTEDO may cause …

The dose of AUSTEDO may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg. Administer total daily dosages of 12 mg or above in …

2.1 Dosing Information The dose of AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. When first prescribed to patients who are …

Discontinuation and Interruption of Treatment Treatment with AUSTEDO can be discontinued without tapering. Following treatment interruption of greater than one week, AUSTEDO therapy should be re …

Mar 9, 2025 · Austedo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

What to expect during treatment Once your healthcare provider prescribes AUSTEDO XR® to help treat your Tardive Dyskinesia (TD), it’s important to know what to expect. The timeline below provides an …

Two VMAT2 inhibitors, valbenazine (Ingrezza) and deutetrabenazine (Austedo) have been FDA approved to treat TD since the last edition of the Black Book. While some improvement in TD is often seen in …

If a patient develops parkinsonism during treatment with AUSTEDO XR or AUSTEDO, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

In cases in which follow-up clinical information was available, parkinsonism was reported to resolve following discontinuation of Austedo therapy. If a patient develops parkinsonism during treatment …

If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. Parkinsonism: AUSTEDO XR and AUSTEDO may cause …